Literature DB >> 22476860

Conservative management of post-transplant central nervous system lymphoma.

Shahul H Valavoor1, Zubair Ashraf, Rawan Narwal, Shobha Ratnam.   

Abstract

Primary CNS lymphoma (PCNSL) is a rare B cell variant non-Hodgkins lymphoma that is confined to the brain, leptomeninges, spinal cord and eyes. Its incidence is increasing, primarily due to increase in the number of organ transplantations being undertaken. The majority of the PTLD (post-transplant lymphoproliferative disorder) is seen in kidney transplant recipients simply because they constitute a larger group of transplant recipients each year as compared to other solid organ transplantations. Primary infection of previously infected EBV seronegative patients and immunosuppression are found to be the main etiologic factors in the development of PTLD-PCNSL. There are no clear guidelines on treatment regimens, and it should be individualized according to patient comorbidities. We report a case of PCNS lymphoproliferative disorder in a kidney transplant recipient, which underwent complete remission with decreasing immunosuppression. The patient could not undergo chemotherapy/radiotherapy due to underlying comorbidities. We highlight the available treatment modalities for PTLD-PCNSL.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22476860     DOI: 10.1007/s11255-012-0146-8

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  11 in total

Review 1.  Primary CNS lymphoma: clinical presentation, pathological classification, molecular pathogenesis and treatment.

Authors:  U Schlegel; I G Schmidt-Wolf; M Deckert
Journal:  J Neurol Sci       Date:  2000-12-01       Impact factor: 3.181

Review 2.  Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations.

Authors:  Deepa Jagadeesh; Bruce A Woda; Jacqueline Draper; Andrew M Evens
Journal:  Curr Treat Options Oncol       Date:  2012-03

Review 3.  Primary central nervous system lymphoma.

Authors:  Elizabeth R Gerstner; Tracy T Batchelor
Journal:  Arch Neurol       Date:  2010-03

4.  A case of Epstein-Barr virus associated post-transplant lymphoproliferative disorder with CNS involvement: pathological findings at both biopsy and autopsy.

Authors:  Makiko Suzuki; Isao Kosugi; Tatsuhiro Terada; Kentarou Shirakawa; Hitoshi Suzuki; Satoshi Kono; Hiroaki Miyajima
Journal:  Neuropathology       Date:  2010-12-06       Impact factor: 1.906

Review 5.  Glucocorticoid treatment of primary CNS lymphoma.

Authors:  M Weller
Journal:  J Neurooncol       Date:  1999-07       Impact factor: 4.130

Review 6.  Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy.

Authors:  Andrew M Evens; Rupali Roy; Danielle Sterrenberg; Michelle Z Moll; Amy Chadburn; Leo I Gordon
Journal:  Curr Oncol Rep       Date:  2010-11       Impact factor: 5.075

7.  Central nervous system lymphoproliferative disorder in pediatric kidney transplant recipients.

Authors:  Avram Z Traum; Nancy M Rodig; Monika E Pilichowska; Michael J G Somers
Journal:  Pediatr Transplant       Date:  2006-06

Review 8.  Therapeutic challenges in primary CNS lymphoma.

Authors:  Patrick G Morris; Lauren E Abrey
Journal:  Lancet Neurol       Date:  2009-06       Impact factor: 44.182

9.  Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report.

Authors:  Robert Cavaliere; Gina Petroni; Maria B Lopes; David Schiff
Journal:  Cancer       Date:  2010-02-15       Impact factor: 6.860

10.  Epstein-Barr virus-associated T/NK cell-type central nervous system lymphoma which manifested as a post-transplantation lymphoproliferative disorder in a renal transplant recipient.

Authors:  Nobuhiko Omori; Hisashi Narai; Tomotaka Tanaka; Shinichiro Tanaka; Ichiro Yamadori; Koichi Ichimura; Tadashi Yoshino; Koji Abe; Yasuhiro Manabe
Journal:  J Neurooncol       Date:  2007-12-06       Impact factor: 4.130

View more
  1 in total

1.  Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry.

Authors:  Heiner Zimmermann; Mirko Nitsche; Christiane Pott; Petra Reinke; Nina Babel; Robert M Hermann; Ingeborg A Hauser; Dennis Hahn; Matthias Ritgen; Claudia Pietschmann; Wolfram Klapper; Ioannis Anagnostopoulos; Ralf U Trappe
Journal:  Ann Hematol       Date:  2021-05-11       Impact factor: 3.673

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.